Friday, October 26, 2007
Florida-based electronic data capture (EDC) provider OmniComm Systems inked 10 new contracts during the third quarter of 2007. The additional deals bring the company’s total contracts to 35 for the year.
Palo Alto, Calif.-based Bayhill Therapeutics reported positive results from a phase IIb trial of BHT-3009 for the treatment of multiple sclerosis. BHT-3009 is a gene therapy drug that delivers DNA that instructs cells to produce myelin basic protein (MBP). Myelin is the phospholipid sheath that surrounds neurons and is the target of many autoimmune diseases such as MS.
Massachusetts-based contract research organization (CRO) Averion International has sold its clinical staffing services unit to members of the company’s management. The new owners are Harvey Greenawalt and Philip Clark.